

The background of the slide is a dark, abstract composition. It features a series of thin, white, curved lines that sweep across the frame, creating a sense of motion and depth. On the right side, there is a more defined, three-dimensional structure that resembles a modern cable-stayed bridge or a futuristic architectural element, with multiple white cables fanning out from a central point. The overall aesthetic is high-tech and architectural.


# AMR surveillance in Kerala : initiative, approach and networks

Dr Aravind R  
HOD Infectious Diseases  
Govt MCH Thiruvananthapuram





## Increasing prevalence and dissemination of NDM-1 metallo- $\beta$ -lactamase in India: data from the SMART study (2009)

Christine Lascols , Meredith Hackel, Steven H. Marshall, Andrea M. Hujer, Sam Bouchillon, Robert Badal, Daryl Hoban, Robert A. Bonomo

*Journal of Antimicrobial Chemotherapy*, Volume 66, Issue 9, September 2011, Pages 1992–





GAP-AMR


- 2015

NAP-AMR

- 2017

KARSAP

- 2018



# Strategic priorities –KARSAP



Improve awareness and understanding of AMR-communication, education, training



Strengthen knowledge and evidence base through surveillance and research




Reduce infection through effective sanitation, hygiene and infection prevention methods



Optimize and regulate the use of antimicrobials in human and animal health



Research priorities





# AMR surveillance

- For assessing the burden of AMR & for providing the information for action in support of local, national & global strategies
- Tracks changes in microbial populations
- Permits the early detection of resistant strains of public health importance
- Supports the prompt notification & investigation of outbreaks
- Surveillance findings are needed to guide policy recommendations & to assess the impact of resistance containment interventions



# Antibiogram

- Presentation of cumulative AST data from a single institution on an annual basis.
- Monitor resistance trends
- Reveal emergence of potential novel resistance mechanisms.
- Aid clinicians in empiric treatment of infections
- CLSI guidelines [M 39-A 4]- for preparation of cumulative antibiograms.



# Activities

- Strengthening & standardization of Microbiology labs.
- Establishing a nodal centre for HCAI surveillance and training at MCH TVM.
- Whole genome sequencing of colistin resistant isolates in kerala-RGCB

# AMR surveillance – Kerala

1. GMC Trivandrum
2. GMC Kozhikode
3. GMC Thrissur
4. GMC Kottayam
5. GMC Alappuzha
6. GMC Ernakulam
7. GMC Manjeri
8. GMC Kollam
9. GH Ernakulam
10. State PH Lab,  
Trivandrum



# AMR surveillance

- Based on National Policy for Control of AMR, 2011 & National Action Plan on AMR (NAP-AMR) 2017-21

## **Identification of infections of public health importance for surveillance**

1. Blood stream infections (BSIs)
2. Skin and soft tissue infections (SSTI)
3. Respiratory tract infections (RTIs)
4. Urinary tract infections (UTI)

# 6 pathogens for AMR surveillance

1. *Acinetobacter* spp
2. *E. coli*
3. *Klebsiella* spp
4. *Pseudomonas aeruginosa*
5. *Staphylococcus aureus*
6. *Enterococcus* spp

**GNB**

**GPC**



**Hospital acquired  
infection**



**Surveillance of  
antimicrobial resistance/  
Antibiotic consumption**

**Cumulative antibiogram (Hospital/Community)**

**Antibiotic policy**

**Standard treatment guidelines**

**Antimicrobial stewardship**

# Priority Pathogen Isolates, 2018


Priority pathogens	Number of blood isolates	Number of urine isolates	Number of aspirated pus isolates	Number of other body fluid* isolates
<i>S. aureus</i>	67	12	338	3
<i>E. coli</i>	75	1281	307	13
<i>Klebsiella species</i>	108	474	281	23
<i>Enterococcus species</i>	36	64	54	7
<i>Pseudomonas aeruginosa</i>	58	95	105	12
<i>Acinetobacter species</i>	110	36	51	17
<i>Salmonella – Typhi &amp; Paratyphi</i>	# Blood isolates	# Stool Isolates		
	1	0		

\*Pleural fluid, CSF, synovial fluid, ascites

# % of ESBL producers

## % of ESBL producers (India)


<i>Acinetobacter</i> spp	65
<i>E. coli</i>	61
<i>Klebsiella</i> spp	62
<i>Pseud. aeruginosa</i>	65



# Carbapenem resistance

## Carbapenem resistance (India)

<i>Acinetobacter</i> spp	70
<i>E. coli</i>	12
<i>Klebsiella</i> spp	51
<i>Pseud. aeruginosa</i>	42




# Gram positives

## Resistance (India)


MRSA 47

VRE 12







# ESBL production



# Carbapenem resistance



# Gram positives





# National AMR surveillance network

- Submit 1% of bacterial isolates on quarterly basis to NCDC for quality control testing
- Vancomycin, Carbapenem & Colistin resistant isolates – molecular characterization
- Share HAIs surveillance data- **ready to join National HAI surveillance net work.**
- Share antimicrobial consumption data .
- Preserve the isolates for future need

# NCDC 2016

Condition	Likely Causative Organisms	Empiric antibiotics (presumptive antibiotics)	Alternative antibiotics	Comments
<i>Acute uncomplicated Cystitis</i>	<i>E.coli</i> , <i>Staphylococcus saprophylticus</i> (in sexually active young women), <i>Klebsiella pneumoniae</i>	Nitrofurantoin 100 mg BD for 7 days or Cotrimoxazole 960mg BD for 3-5 days or Ciprofloxacin 500 mg BD for 3-5 days	Cefuroxime 250 mg BD for 3-5 days	Get urine cultures before antibiotics & modify therapy based on sensitivities.
<i>Acute uncomplicated Pyelonephritis</i>	<i>E.coli</i> , <i>Staphylococcus saprophylticus</i> (in sexually active young women), <i>Klebsiella pneumoniae</i> , <i>Proteus mirabilis</i>	Amikacin 1 g OD IM/IV or Gentamicin 7 mg/kg/day OD  (Monitor renal function closely and rationalise according to culture report) Complete total duration of 14 days	Piperacillin-Tazobactam 4.5g IV 6 hourly or Cefoperazone-Sulbactam 3g IV 12 hourly or Ertapenem 1 g IV OD	Urine culture and susceptibilities need to be collected before starting antimicrobial treatment to guide treatment.



# ICMR 2017

Clinical Condition	Common Pathogens	Empiric AMA	Alternate AMA	Comments
Acute Cystitis (in absence of cultures)	<i>E.coli</i> , <i>Proteus</i> sp <i>Klebsiella</i> sp.	<ul style="list-style-type: none"> <li>● Nitrofurantoin 100 mg BD for 7 days</li> <li>● Cotrimoxazole 500/125 mg BD for 3-5 days</li> <li>● Ciprofloxacin 500 mg BD for 3-5 days</li> </ul>	<ul style="list-style-type: none"> <li>● Cefuroxime 250 mg BD for 3-5 days</li> <li>● Cefixime 400mg BD for 5 days</li> </ul>	<i>Staphylococcus saprophyticus</i> (in sexually active young women) but is not common in India. In pregnancy the duration of treatment is longer
Acute Pyelonephritis (individualized based on data from each center) If blood culture is positive, a carbapenem is preferred)	<i>E.coli</i> , <i>Klebsiella</i> sp <i>Proteus</i> sp <i>S. aureus</i>	<ul style="list-style-type: none"> <li>● Piperacillin tazobactam 4.5 gm IV 6 hourly for 10 days</li> <li>● Ertapenem 1 g IV OD for 7 days</li> </ul>	<ul style="list-style-type: none"> <li>● Imipenem 500 mg IV 8 hourly for 10 days or</li> <li>● Inj Amikacin 5mg/kg IV once daily x 10 days</li> </ul>	<p>Urine and blood culture should be done before start of treatment.</p> <p>Amikacin 1gm OD IV or Gentamicin 7 mg/kg as prescribed doses . Close monitor on renal parameters is needed and watch out for</p>



# KARS-Net objectives

- Foster standardization, strengthening and expansion of AMR surveillance in Kerala
- Analyse and report KARS-Net data to State Government and NCDC on regular basis
- Contribute towards the estimation of extent, burden and monitoring of AMR in Kerala
- Detect emerging resistance and its spread in Kerala

# KARS-Net prerequisites

## A. Essential

- Regular documentation of internal quality control (IQC) for antimicrobial susceptibility testing using standard strains and media
- Continuing participation in Microbiology EQAS for at least last 2 years, with minimum 75% score in identification/susceptibility testing
- Willingness to participate and share AMR data with KARS-Net

# KARS-Net prerequisites

## B. Desirable


- Accreditation of laboratory or institute by National Accreditation Board for Testing and Calibration Laboratories (NABL) or National Accreditation Board for Hospitals & Healthcare Providers (NABH)
- Regular generation of institutional antibiograms
- Using WHONET or other laboratory software to capture AMR data electronically

# Future activities

- 10 more institutions shall be inducted into KARS-NET from the list of institutions & labs in Kerala, based on their capacity for AMR testing & Surveillance- assessed using-
- The initial focus of surveillance in KARS-NET shall be bacterial drug resistance
- Key staff from participating institutions shall be trained for
  - a) Standardized AST
  - b) Data management- WHONET training
  - c) Development of antibiograms
  - d) Preparation of SOPs for all procedures



# The Pareto Principle – why you shouldn't focus on everything






# HAI SURVEILLANCE

- Investing in infection control is the need of the hour  
1 dollar spent on IPC translates to 246 dollars saved in patient care\*
- HAI surveillance data – VAP, CAUTI, CLABSI, SSI – link nurses from ICUs
- DME – conducted 1 week workshop & training for nurses of all MCHs in IPC & HAI rate calculation – link nurses

\* Study by Sanjeev Singh, et al from AIMS

# VAP Metrics MDICU 2018



A close-up photograph of a hand with light skin and pink nail polish planting a small, light-colored seed into dark, rich soil. The background is a soft, out-of-focus green and yellow gradient. The quote is overlaid at the top in a white, serif font.

DON'T JUDGE EACH DAY BY THE HARVEST  
YOU REAP BUT BY THE SEEDS YOU PLANT.

---

ROBERT LOUIS STEVENSON  
NOVELIST/POET (DECEASED 1894)





# SMALL GROUP LEARNING







**“ALONE WE CAN  
DO SO LITTLE;  
TOGETHER WE  
CAN DO SO MUCH.”**

- Helen Keller



Thank you